APFID

Home > Latest News on ID > Interesting Papers

LOGIN
Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions
Vaccine. 2009;27(36):4891-904
Date: 2009-07-27   Read: 157450

Vaccine. 2009 Aug 6;27(36):4891-904

Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions

Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M

Streptococcus pneumoniae infections in adults are associated with substantial morbidity, mortality, and costs. A literature review was conducted to identify strengths and limitations of the cost-effectiveness of pneumococcal polysaccharide vaccine studies. A comparative analysis of the impact of model parameters on cost-effectiveness ratios was complemented by systematic assessment of the studies. We identified 11 economic evaluations of pneumococcal polysaccharide vaccine (PPV-23) in adults. In general, all 11 studies found that vaccination with PPV-23 is a cost-effective, and in some cases a cost-saving strategy for the prevention of invasive pneumococcal disease (IPD). The systematic assessment indicated that the results of the cost-effectiveness studies of PPV-23 are influenced by the values applied to vaccine efficacy, IPD incidence and case-fatality.



Next Contribution of genetically restricted, methicillin-susceptible strains to the ongoing epidemic of community-acquired S. aureus infections 2009-07-27 159953
Previous Hyper-recombination, diversity, and antibiotic resistance in pneumococcus
Science. 2009;324(5933):1454-7
2009-07-27 158909
޴ٷΰ ΰ